Company profile
Mereo BioPharma Group plc
NASDAQ:MREOBiotechnology: Pharmaceutical Preparations
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03636347 | phase2 | completed | 2018-10-29 | 2022-03-02 | Mereo BioPharma | A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo. |
| NCT02908074 | phase2 | completed | 2016-11-15 | 2018-09-08 | Mereo BioPharma | A 6 Month Safety Extension Study of MBGS205 |
| NCT01116440 | phase2 | terminated | 2010-04-15 | 2011-07-01 | Mereo BioPharma | A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis |
| NCT04761198 | phase1_2 | completed | 2021-03-23 | 2023-10-30 | Mereo BioPharma | A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors |
| NCT01190475 | phase2 | completed | 2010-07-01 | 2011-09-01 | Mereo BioPharma | BGS649 Monotherapy in Moderate to Severe Endometriosis Patients |
FDA applications (0)
No records yet.